Claims
- 1. A method of treating traumatic brain injury or hypoxic or ischemic stroke in a mammal, comprising administering to said mammal:
(a) a neutrophil inhibiting factor (NIF) or a pharmaceutically acceptable salt thereof; and (b) an NR2B subtype selective NMDA receptor antagonizing compound or a pharmaceutically acceptable salt thereof; wherein the active agents “a” and “b” above are present in amounts that render the combination of the two agents effective in treating hypoxic or ischemic stroke.
- 2. A pharmaceutical composition for treating traumatic brain injury or hypoxic or ischemic stroke in a mammal, comprising:
(a) a neutrophil inhibiting factor (NIF) or a pharmaceutically acceptable salt thereof; (b) an NR2B subtype selective NMDA receptor antagonizing compound or a pharmaceutically acceptable salt thereof; and c) a pharmaceutically acceptable carrier; wherein the active agents “a” and “b” are present in such composition in amounts that render the combination of the two agents effective in treating such disorder.
- 3. The method of claim 1, wherein said NMDA receptor antagonist is an NR2B selective NMDA receptor antagonist of the formula
- 4. The method of claim 1, wherein said NR2B subtype selective NMDA receptor antagonist is (+)-(1S, 2S)-1-(4-hydroxy-phenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol or a pharmaceutically acceptable acid addition salt thereof.
- 5. The method of claim 1, wherein said NR2B subtype selective NMDA receptor antagonist is (1S, 2S)-1-(4-hydroxy-3-methoxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol or a pharmaceutically acceptable acid addition salt thereof.
- 6. The method of claim 1, wherein said NR2B subtype selective NMDA receptor antagonist is (3R,4S)-3-(4-(4-fluorophenyl)-4-hydroxypiperidin-1-yl)-chroman-4,7-diol or a pharmaceutically acceptable acid addition salt thereof.
- 7. The method of claim 1, wherein said NR2B subtype selective NMDA receptor antagonist is (1R*, 2R*)-1-(4-hydroxy-3-methylphenyl)-2-(4-(4-fluorophenyl)-4-hydroxypiperidin-1-yl)-propan-1-ol-mesylate.
- 8. The method of claim 1, wherein the NR2B subtype selective NMDA receptor antagonist has a ratio of NR2B receptor activity to α1-adrenergic receptor activity that is at least about 3:1.
- 9. The method of claim 1, wherein the NMDA receptor antagonist has a ratio of NR2B receptor activity to a,-adrenergic receptor activity that is at least about 5:1.
- 10. The pharmaceutical composition of claim 2, wherein said NMDA receptor antagonist is an NR2B selective NMDA receptor antagonist of the formula
- 11. The pharmaceutical composition of claim 2, wherein said NR2B subtype selective NMDA receptor antagonist is (+)-(1S, 2S)-1-(4-hydroxy-phenyl)-2-(4-hydroxy4-phenylpiperidino)-1-propanol or a pharmaceutically acceptable acid addition salt thereof.
- 12. The pharmaceutical composition of claim 2, wherein said NR2B subtype selective NMDA receptor antagonist is (1S, 2S)-1-(4-hydroxy-3-methoxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol or a pharmaceutically acceptable acid addition salt thereof.
- 13. The pharmaceutical composition of claim 2, wherein said NR2B subtype selective NMDA receptor antagonist is (3R,4S)-3-(4-(4-fluorophenyl)-4-hydroxypiperidin-1-yl)-chroman-4,7-diol or a pharmaceutically acceptable acid addition salt thereof.
- 14. The pharmaceutical composition of claim 2, wherein said NR2B subtype selective NMDA receptor antagonist is (1R*, 2R*)-1-(4-hydroxy-3-methylphenyl)-2-(4-(4-fluorophenyl)-4-hydroxypiperidin-1-yl)-propan-1-ol-mesylate.
- 15. The pharmaceutical composition of claim 2, wherein the NR2B subtype selective NMDA receptor antagonist has a ratio of NR2B receptor activity to α1-adrenergic receptor activity that is at least about 3:1.
- 16. The pharmaceutical composition of claim 2, wherein the NMDA receptor antagonist has a ratio of NR2B receptor activity to α1-adrenergic receptor activity that is at least about 5:1.
Parent Case Info
[0001] This application claims priority under 35 U.S.C. 119(e) of U.S. Provisional Application No. 60/230,944, filed Sep. 6, 2000.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60230944 |
Sep 2000 |
US |